Staphylococcus aureus is pathogenic to humans with worldwide health care concern due to its ability to evade the immune system and develop resistance to multiple drugs. Reg family proteins are C-type lectins with anti...Staphylococcus aureus is pathogenic to humans with worldwide health care concern due to its ability to evade the immune system and develop resistance to multiple drugs. Reg family proteins are C-type lectins with antimicrobial properties. Bacterial aggregation through binding to microbial cell surface sugar and/or lipid moieties is key mechanism employed in the process. In the present study we have analysed the antimicrobial effect of human REG Iα on S. aureus. Aggregation of mid-log phase culture of S. aureus was observed in presence of purified recombinant REG Iα. Therefore REG Iα can be applied in eliminating S. aureus infections in humans.展开更多
Accumulating evidence suggests that C-type lectin-like receptor-2(CLEC-2)plays an important role in atherothrombosis.In this case-control study,we investigated the association between CLEC-2 and incidence of coronary ...Accumulating evidence suggests that C-type lectin-like receptor-2(CLEC-2)plays an important role in atherothrombosis.In this case-control study,we investigated the association between CLEC-2 and incidence of coronary artery disease(CAD).A total of 216 patients,including 14 cases of stable angina pectoris(SAP,non-ACS)and 202 cases of acute coronary syndrome(ACS),and 89 non-CAD control subjects were enrolled.Plasma levels of soluble CLEC-2(sCLEC-2)were measured using the enzyme-linked immunosorbent assay(ELISA).Compared with the control group(65.69(55.36–143.22)pg/mL),the plasma levels of sCLEC-2 were significantly increased in patients with CAD(133.67(88.76–220.09)pg/mL)and ACS(134.16(88.88–225.81)pg/mL).The multivariate adjusted odds ratios(95%confidence interval)of CAD reached 2.01(1.52–2.66)(Ptrend<0.001)for each 1-quartile increase in sCLEC-2.Restricted cubic splines showed a positive dose-response association between sCLEC2 and CAD incidence(Plinearity<0.001).The addition of sCLEC-2 to conventional risk factors improved the C statistic(0.821 vs.0.761,P=0.004)and reclassification ability(net reclassification improvement:57.45%,P<0.001;integrated discrimination improvement:8.27%,P<0.001)for CAD.In conclusion,high plasma sCLEC-2 is independently associated with CAD risk,and the prognostic value of sCLEC-2 may be evaluated in future prospective studies.展开更多
Breast and prostate cancer are the leading causes of death in females and males, respectively. Triple negative breast cancer (TNBC) does not express the estrogen receptor, progesterone receptor, or human epidermal gro...Breast and prostate cancer are the leading causes of death in females and males, respectively. Triple negative breast cancer (TNBC) does not express the estrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2, resulting in limited treatment options. Androgen deprivation therapy is the standard care for prostate cancer patients;however, metastasis and recurrence are seen in androgen-independent prostate cancer. Both prostate and breast cancer show higher resistance after recurrence and metastasis, which increases the difficulty of treatment. Natural killer (NK) cells play a critical role during innate immunity and tumor recognition and elimination. NK cell function is determined by a delicate balance of inhibitory signals and activation signals received through cell surface receptors. Lectin-like transcript 1 (LLT1, CLEC2D, OCIL) is a ligand of NK cell inhibitory receptor NKRP1A (CD161). Several studies have that reported higher expression of LLT1 is associated with the development of various tumors. Our studies revealed that TNBC and prostate cancer cells express higher levels of LLT1. In the presence of a monoclonal antibody against LLT1, NK cell-mediated killing of TNBC and prostate cancer cells were greatly enhanced. This review highlights the potential that using monoclonal antibodies to block LLT1 - NKRP1A interactions could be an effective immunotherapeutic approach to treat triple negative breast cancer and prostate cancer.展开更多
文摘Staphylococcus aureus is pathogenic to humans with worldwide health care concern due to its ability to evade the immune system and develop resistance to multiple drugs. Reg family proteins are C-type lectins with antimicrobial properties. Bacterial aggregation through binding to microbial cell surface sugar and/or lipid moieties is key mechanism employed in the process. In the present study we have analysed the antimicrobial effect of human REG Iα on S. aureus. Aggregation of mid-log phase culture of S. aureus was observed in presence of purified recombinant REG Iα. Therefore REG Iα can be applied in eliminating S. aureus infections in humans.
基金supported by grants from the National Natural Science Foundation of China(Nos.81870325,81620108001,and 91739302 to Li Zhu)the Priority Academic Program Development of Jiangsu Higher Education Institutions of China and Suzhou Key laboratory of Thrombosis and Vascular Diseases(to Li Zhu)+1 种基金the Suzhou Science and Technology Project Foundation(No.SYS201721 to Li Xiang)the Young Investigator Pre-research Foundation of the Second Affiliated Hospital of Soochow University(No.SDFEYQN1717 to Tao You).
文摘Accumulating evidence suggests that C-type lectin-like receptor-2(CLEC-2)plays an important role in atherothrombosis.In this case-control study,we investigated the association between CLEC-2 and incidence of coronary artery disease(CAD).A total of 216 patients,including 14 cases of stable angina pectoris(SAP,non-ACS)and 202 cases of acute coronary syndrome(ACS),and 89 non-CAD control subjects were enrolled.Plasma levels of soluble CLEC-2(sCLEC-2)were measured using the enzyme-linked immunosorbent assay(ELISA).Compared with the control group(65.69(55.36–143.22)pg/mL),the plasma levels of sCLEC-2 were significantly increased in patients with CAD(133.67(88.76–220.09)pg/mL)and ACS(134.16(88.88–225.81)pg/mL).The multivariate adjusted odds ratios(95%confidence interval)of CAD reached 2.01(1.52–2.66)(Ptrend<0.001)for each 1-quartile increase in sCLEC-2.Restricted cubic splines showed a positive dose-response association between sCLEC2 and CAD incidence(Plinearity<0.001).The addition of sCLEC-2 to conventional risk factors improved the C statistic(0.821 vs.0.761,P=0.004)and reclassification ability(net reclassification improvement:57.45%,P<0.001;integrated discrimination improvement:8.27%,P<0.001)for CAD.In conclusion,high plasma sCLEC-2 is independently associated with CAD risk,and the prognostic value of sCLEC-2 may be evaluated in future prospective studies.
文摘Breast and prostate cancer are the leading causes of death in females and males, respectively. Triple negative breast cancer (TNBC) does not express the estrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2, resulting in limited treatment options. Androgen deprivation therapy is the standard care for prostate cancer patients;however, metastasis and recurrence are seen in androgen-independent prostate cancer. Both prostate and breast cancer show higher resistance after recurrence and metastasis, which increases the difficulty of treatment. Natural killer (NK) cells play a critical role during innate immunity and tumor recognition and elimination. NK cell function is determined by a delicate balance of inhibitory signals and activation signals received through cell surface receptors. Lectin-like transcript 1 (LLT1, CLEC2D, OCIL) is a ligand of NK cell inhibitory receptor NKRP1A (CD161). Several studies have that reported higher expression of LLT1 is associated with the development of various tumors. Our studies revealed that TNBC and prostate cancer cells express higher levels of LLT1. In the presence of a monoclonal antibody against LLT1, NK cell-mediated killing of TNBC and prostate cancer cells were greatly enhanced. This review highlights the potential that using monoclonal antibodies to block LLT1 - NKRP1A interactions could be an effective immunotherapeutic approach to treat triple negative breast cancer and prostate cancer.
